249 related articles for article (PubMed ID: 33921332)
21. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB
Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400
[TBL] [Abstract][Full Text] [Related]
22. Imidazole[1,5-a]pyridine derivatives as EGFR tyrosine kinase inhibitors unraveled by umbrella sampling and steered molecular dynamics simulations.
Truong DT; Ho K; Nhi HTY; Nguyen VH; Dang TT; Nguyen MT
Sci Rep; 2024 May; 14(1):12218. PubMed ID: 38806555
[TBL] [Abstract][Full Text] [Related]
23. Design, Synthesis, Cytotoxic Evaluation and Molecular Docking of New Fluoroquinazolinones as Potent Anticancer Agents with Dual EGFR Kinase and Tubulin Polymerization Inhibitory Effects.
Zayed MF; Ahmed S; Ihmaid S; Ahmed HEA; Rateb HS; Ibrahim SRM
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29891789
[TBL] [Abstract][Full Text] [Related]
24. Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2.
Sangande F; Julianti E; Tjahjono DH
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096664
[TBL] [Abstract][Full Text] [Related]
25.
Shi Z; Chen J; Guo X; Cheng L; Guo X; Yu T
J Cancer Res Ther; 2018 Jan; 14(1):18-23. PubMed ID: 29516953
[TBL] [Abstract][Full Text] [Related]
26. Structure-Based Drug Design Studies Toward the Discovery of Novel Chalcone Derivatives as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors.
Al-Anazi M; Al-Najjar BO; Khairuddean M
Molecules; 2018 Dec; 23(12):. PubMed ID: 30563058
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis and
Le Y; Gan Y; Fu Y; Liu J; Li W; Zou X; Zhou Z; Wang Z; Ouyang G; Yan L
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):555-564. PubMed ID: 31967481
[TBL] [Abstract][Full Text] [Related]
28. Cell-penetrable nanobodies (transbodies) that inhibit the tyrosine kinase activity of EGFR leading to the impediment of human lung adenocarcinoma cell motility and survival.
Tabtimmai L; Suphakun P; Srisook P; Kiriwan D; Phanthong S; Kiatwuthinon P; Chaicumpa W; Choowongkomon K
J Cell Biochem; 2019 Oct; 120(10):18077-18087. PubMed ID: 31172597
[TBL] [Abstract][Full Text] [Related]
29. Discovery of novel thienoquinoline-2-carboxamide chalcone derivatives as antiproliferative EGFR tyrosine kinase inhibitors.
Abdelbaset MS; Abdel-Aziz M; Ramadan M; Abdelrahman MH; Abbas Bukhari SN; Ali TFS; Abuo-Rahma GEA
Bioorg Med Chem; 2019 Mar; 27(6):1076-1086. PubMed ID: 30744932
[TBL] [Abstract][Full Text] [Related]
30. New phthalimide-based derivatives as EGFR-TK inhibitors: Synthesis, biological evaluation, and molecular modeling study.
Mansour NI; El-Sayed SM; El-Gohary NS; Abdel-Aziz NI; El-Subbagh HI; Ghaly MA
Bioorg Chem; 2022 Oct; 127():105966. PubMed ID: 35728294
[TBL] [Abstract][Full Text] [Related]
31. Combined Treatment with Triptolide and Tyrosine Kinase Inhibitors Synergistically Enhances Apoptosis in Non-small Cell Lung Cancer H1975 Cells but Not H1299 Cells through EGFR/Akt Pathway.
Tong X; Jiang P; Li Y; Guo L; Zhang HM; Zhang BK; Yan M
Chem Pharm Bull (Tokyo); 2019 Aug; 67(8):864-871. PubMed ID: 31142691
[TBL] [Abstract][Full Text] [Related]
32. A novel cyclic NP1 reveals obstruction of EGFR kinase activity and attenuation of EGFR-driven cell lines.
Jiwacharoenchai N; Tabtimmai L; Kiriwan D; Suwattanasophon C; Seetaha S; Sinthuvanich C; Choowongkomon K
J Cell Biochem; 2022 Feb; 123(2):248-258. PubMed ID: 34633106
[TBL] [Abstract][Full Text] [Related]
33. Computational Evaluation and In Vitro Validation of New Epidermal Growth Factor Receptor Inhibitors.
Gómez-Ganau S; Castillo J; Cervantes A; de Julián-Ortiz JV; Gozalbes R
Curr Top Med Chem; 2020; 20(18):1628-1639. PubMed ID: 32493189
[TBL] [Abstract][Full Text] [Related]
34. New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: Design, synthesis, cytotoxicity evaluation and in silico studies.
El-Sayed NA; Nour MS; Salem MA; Arafa RK
Eur J Med Chem; 2019 Dec; 183():111693. PubMed ID: 31539778
[TBL] [Abstract][Full Text] [Related]
35. Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer.
Yi Y; Wang L; Zhao D; Huang S; Wang C; Liu Z; Sun H; Liu K; Ma X; Li Y
Chem Biol Drug Des; 2018 Dec; 92(6):1988-1997. PubMed ID: 30030903
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of JAK1/2 can overcome EGFR-TKI resistance in human NSCLC.
Kim DM; Kim MJ; Moon JH; Lee EY; Hong JK; Lee S; Koh DI; Ryu YS; Kim SM; Jung SA; Shin JS; Kim J; Park YS; Hong SW; Lee SH; Jung J; Park SS; Kim DY; Kim EH; Jeong HR; Gong JH; Kim J; Chan Kim S; Yu HN; Ki SY; Kim TW; Jin DH
Biochem Biophys Res Commun; 2020 Jun; 527(1):305-310. PubMed ID: 32446385
[TBL] [Abstract][Full Text] [Related]
37. Synthesis, anticancer and apoptosis-inducing activities of quinazoline-isatin conjugates: epidermal growth factor receptor-tyrosine kinase assay and molecular docking studies.
El-Azab AS; Al-Dhfyan A; Abdel-Aziz AA; Abou-Zeid LA; Alkahtani HM; Al-Obaid AM; Al-Gendy MA
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):935-944. PubMed ID: 28718672
[TBL] [Abstract][Full Text] [Related]
38. Imidazo[1,2-a]quinazolines as novel, potent EGFR-TK inhibitors: Design, synthesis, bioactivity evaluation, and in silico studies.
Hasanvand Z; Oghabi Bakhshaiesh T; Peytam F; Firoozpour L; Hosseinzadeh E; Motahari R; Moghimi S; Nazeri E; Toolabi M; Momeni F; Bijanzadeh H; Khalaj A; Baratte B; Josselin B; Robert T; Bach S; Esmaeili R; Foroumadi A
Bioorg Chem; 2023 Apr; 133():106383. PubMed ID: 36764231
[TBL] [Abstract][Full Text] [Related]
39. Conformational Insight on WT- and Mutated-EGFR Receptor Activation and Inhibition by Epigallocatechin-3-Gallate: Over a Rational Basis for the Design of Selective Non-Small-Cell Lung Anticancer Agents.
Minnelli C; Laudadio E; Mobbili G; Galeazzi R
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32138321
[TBL] [Abstract][Full Text] [Related]
40. 2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study.
AboulWafa OM; Daabees HMG; Badawi WA
Bioorg Chem; 2020 Jun; 99():103798. PubMed ID: 32247112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
